HIV-positive TB co-infected patients are at increased risk of multidrug-resistant (MDR)-TB compared to HIV-negative patients. Co-treatment of MDR-TB and HIV is common particularly in Sub-Saharan Africa where the co-morbidity is endemic. We discuss potential cellular metabolic pathway–mediated drug–drug interactions and the possible effect on HIV treatment outcomes of commonly prescribed antiretroviral therapy.
CITATION STYLE
Mukonzo, J., Aklillu, E., Marconi, V., & Schinazi, R. F. (2019, June 1). Potential drug–drug interactions between antiretroviral therapy and treatment regimens for multi-drug resistant tuberculosis: Implications for HIV care of MDR-TB co-infected individuals. International Journal of Infectious Diseases. Elsevier B.V. https://doi.org/10.1016/j.ijid.2019.04.009
Mendeley helps you to discover research relevant for your work.